Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. — CFSMEATLAS
Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Freitag, Helma, Szklarski, Marvin, Lorenz, Sebastian et al. · Journal of clinical medicine · 2021 · DOI
Quick Summary
This study examined whether certain antibodies in ME/CFS patients' blood relate to how severe their symptoms are. The researchers tested 116 ME/CFS patients for antibodies that target receptors controlling blood vessel function and other vital processes. They found that patients whose ME/CFS started after an infection had stronger connections between these antibodies and key symptoms like fatigue and muscle pain, suggesting these antibodies might play a role in how the disease develops.
Why It Matters
This research provides potential biological explanations for ME/CFS symptoms—particularly autonomic dysfunction and fatigue—by identifying specific autoantibodies linked to disease severity. Understanding these immune mechanisms could eventually lead to better diagnostic biomarkers and targeted treatments, and may explain why infection-triggered and non-infection-triggered ME/CFS show different symptom patterns.
Observed Findings
Most measured autoantibodies significantly correlated with fatigue and muscle pain severity in patients with infection-triggered ME/CFS onset
Cognitive impairment severity correlated specifically with AT1-R and ETA-R autoantibody levels
Alpha1/2-adrenergic receptor autoantibodies correlated with gastrointestinal symptom severity
Patients with non-infection-triggered ME/CFS showed fewer and different autoantibody correlations compared to infection-triggered disease
Autoantibody profiles varied by symptom domain, suggesting receptor-specific pathophysiological pathways
Inferred Conclusions
Natural regulatory autoantibodies to vasoregulative receptors likely contribute to ME/CFS pathomechanism, particularly in infection-triggered disease
Different receptor-targeted autoantibody pathways may underlie distinct symptom clusters (fatigue/pain, cognitive impairment, gastrointestinal dysfunction)
Infection-triggered and non-infection-triggered ME/CFS may involve distinct immunological mechanisms
Autoantibody profiling could provide biological insight into disease heterogeneity and potentially guide personalized treatment approaches
Remaining Questions
Do these autoantibodies persist over time, and how do their levels change with disease progression or treatment?
What This Study Does Not Prove
This study demonstrates correlation between autoantibodies and symptom severity, but does not prove these antibodies cause ME/CFS or its symptoms. The cross-sectional design captures only a single time point and cannot establish whether the autoantibodies precede symptom development or arise as a consequence of illness. The findings apply specifically to this Berlin cohort and may not generalize to all ME/CFS populations.